Zhao Cui

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5189762/publications.pdf

Version: 2024-02-01

107 papers	2,742 citations	159585 30 h-index	223800 46 g-index
108 all docs	108 docs citations	108 times ranked	2299 citing authors

#	Article	IF	Citations
1	A 16-year-old girl with sudden heart failure and nephrotic syndrome associated with Takayasuâ€™s arteritis. Clinical Research in Cardiology, 2022, 111, 221-226.	3.3	1
2	In-situ monitoring of membrane fouling migration and compression mechanism with improved Ultraviolet technique in membrane bioreactors. Bioresource Technology, 2022, 347, 126684.	9.6	2
3	Anti-phospholipase A2 receptor antibodies directly induced podocyte damage inÂvitro. Renal Failure, 2022, 44, 304-313.	2.1	5
4	Predictors of Kidney Outcomes of Anti-Glomerular Basement Membrane Disease in a Large Chinese Cohort. American Journal of Nephrology, 2022, 53, 397-406.	3.1	8
5	Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2022, 33, 1742-1756.	6.1	33
6	Rituximab for the treatment of refractory anti-glomerular basement membrane disease. Renal Failure, 2022, 44, 1124-1130.	2.1	5
7	The clinical and immunological features of the post-extracorporeal shock wave lithotripsy anti-glomerular basement membrane disease. Renal Failure, 2021, 43, 149-155.	2.1	6
8	Nephrology in China. , 2021, , 251-290.		1
9	Comparison of Ultrastructural Features Between Patients with Mercury-associated Membranous Nephropathy and Idiopathic Membranous Nephropathy. American Journal of the Medical Sciences, 2021, 361, 327-335.	1.1	1
10	Laminin-521 is a Novel Target of Autoantibodies Associated with Lung Hemorrhage in Anti-GBM Disease. Journal of the American Society of Nephrology: JASN, 2021, 32, 1887-1897.	6.1	10
11	Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort. Frontiers in Medicine, 2021, 8, 663680.	2.6	11
12	Effects of hydroxychloroquine on proteinuria in membranous nephropathy. Journal of Nephrology, 2021, , 1.	2.0	4
13	Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 465-470.	0.7	12
14	Epitope Mapping of Human Î±3(IV)NC1-Induced Membranous Nephropathy in Mice. American Journal of Nephrology, 2020, 51, 99-107.	3.1	6
15	Clinical-Pathological Features and Outcome of Atypical Anti-glomerular Basement Membrane Disease in a Large Single Cohort. Frontiers in Immunology, 2020, 11, 2035.	4.8	18
16	The prevalence and immunological features of anti-glomerular basement membrane antibody in patients with HIV. BMC Nephrology, 2020, 21, 429.	1.8	3
17	The Complement C3a and C3a Receptor Pathway in Kidney Diseases. Frontiers in Immunology, 2020, 11, 1875.	4.8	26
18	Complement activation profile of patients with primary focal segmental glomerulosclerosis. PLoS ONE, 2020, 15, e0234934.	2.5	21

#	Article	IF	Citations
19	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	12.8	120
20	Renal leukocyte chemotactic factor 2 (ALECT2)-associated amyloidosis in Chinese patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 134-141.	3.0	11
21	Membranous Nephropathy in Pregnancy. American Journal of Nephrology, 2020, 51, 304-317.	3.1	11
22	A Modified Peptide Derived from Goodpasture Autoantigen Arrested and Attenuated Kidney Injuries in a Rat Model of Anti-GBM Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2020, 31, 40-53.	6.1	7
23	Experimental Antiglomerular Basement Membrane GN Induced by a Peptide from Actinomyces. Journal of the American Society of Nephrology: JASN, 2020, 31, 1282-1295.	6.1	8
24	Complement activation profile of patients with primary focal segmental glomerulosclerosis. , 2020, 15, e0234934.		0
25	Complement activation profile of patients with primary focal segmental glomerulosclerosis. , 2020, 15, e0234934.		0
26	Complement activation profile of patients with primary focal segmental glomerulosclerosis. , 2020, 15, e0234934.		0
27	Complement activation profile of patients with primary focal segmental glomerulosclerosis. , 2020, 15, e0234934.		0
28	Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis. Medicine (United States), 2019, 98, e15303.	1.0	4
29	Complement activation products in the circulation and urine of primary membranous nephropathy. BMC Nephrology, 2019, 20, 313.	1.8	38
30	Risk HLA class II alleles and amino acid residues in myeloperoxidaseâ€“ANCA-associated vasculitis. Kidney International, 2019, 96, 1010-1019.	5.2	18
31	Epitope recognized by anti-glomerular basement membrane (GBM) antibody in a patient with repeated relapse of anti-GBM disease. Experimental and Molecular Pathology, 2019, 107, 165-170.	2.1	2
32	Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney International, 2019, 95, 666-679.	5.2	68
33	Delayed diagnosis of acromegaly in a patient with focal segmental Glomerulosclerosis: a rare case report and literature review. BMC Nephrology, 2019, 20, 435.	1.8	6
34	Acute tubulointerstitial nephritis with germinal centers in antineutrophil cytoplasmic antibody-associated vasculitis. Medicine (United States), 2019, 98, e18178.	1.0	10
35	Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort. Nephrology Dialysis Transplantation, 2018, 33, 1558-1563.	0.7	32
36	Primary glomerular nephropathy among hospitalized patients in a national database in China. Nephrology Dialysis Transplantation, 2018, 33, 2173-2181.	0.7	26

#	Article	IF	Citations
37	The Clinical and Immunologic Features of Patients With Combined Anti-GBM Disease and Castleman Disease. American Journal of Kidney Diseases, 2018, 71, 904-908.	1.9	8
38	The Genetic and Environmental Factors of Primary Membranous Nephropathy: An Overview from China. Kidney Diseases (Basel, Switzerland), 2018, 4, 65-73.	2.5	24
39	Deglycosylation influences the oxidation activity and antigenicity of myeloperoxidase. Nephrology, 2018, 23, 46-52.	1.6	7
40	Fever and prodromal infections in antiâ€glomerular basement membrane disease. Nephrology, 2018, 23, 476-482.	1.6	19
41	T cell responses to peptides of Goodpasture autoantigen in patients with antiâ€glomerular basement membrane disease. Nephrology, 2018, 23, 345-350.	1.6	4
42	Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy. American Journal of Nephrology, 2018, 48, 438-446.	3.1	19
43	Serum uromodulin and progression of kidney disease in patients with chronic kidney disease. Journal of Translational Medicine, 2018, 16, 316.	4.4	32
44	The frequency of ANCA-associated vasculitis in a national database of hospitalized patients in China. Arthritis Research and Therapy, 2018, 20, 226.	3.5	41
45	HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy. Kidney International, 2018, 94, 974-982.	5.2	22
46	Clinical implications of pathological features of primary membranous nephropathy. BMC Nephrology, 2018, 19, 215.	1.8	33
47	Clinical and prognostic significance of glomerular C1q deposits in primary MN. Clinica Chimica Acta, 2018, 485, 152-157.	1.1	18
48	Deglycosylation of myeloperoxidase uncovers its novel antigenicity. Kidney International, 2017, 91, 1410-1419.	5.2	14
49	The critical amino acids of a nephritogenic epitope on human Goodpasture autoantigen for binding to HLA-DRB1*1501. Molecular Immunology, 2017, 88, 1-9.	2.2	8
50	The pathogenicity of T cell epitopes on human Goodpasture antigen and its critical amino acid motif. Journal of Cellular and Molecular Medicine, 2017, 21, 2117-2128.	3.6	10
51	The susceptible <scp>HLA</scp> class <scp>II</scp> alleles and their presenting epitope(s) in Goodpasture's disease. Immunology, 2017, 151, 395-404.	4.4	14
52	Anti-glomerular basement membrane glomerulonephritis with thrombotic microangiopathy: a case report. Immunologic Research, 2017, 65, 769-773.	2.9	4
53	Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety. Renal Failure, 2017, 39, 688-697.	2.1	9
54	Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1642-1651.	4.5	66

#	Article	IF	Citations
55	Concurrent IgG4-related tubulointerstitial nephritis and IgG4 myeloperoxidase-anti-neutrophil cytoplasmic antibody positive crescentic glomerulonephritis. Medicine (United States), 2017, 96, e6707.	1.0	16
56	MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 1651-1664.	6.1	82
57	Plasma from patients with anti-glomerular basement membrane disease could recognize microbial peptides. PLoS ONE, 2017, 12, e0174553.	2.5	12
58	Antibodies against linear epitopes on Goodpasture autoantigen in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Clinical Rheumatology, 2017, 36, 2087-2094.	2.2	3
59	Patients With Combined Membranous Nephropathy and Focal Segmental Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles With Primary Membranous Nephropathy. Medicine (United States), 2016, 95, e3786.	1.0	10
60	Plasma Exchange as an Adjunctive Therapy for Crescentic IgA Nephropathy. American Journal of Nephrology, 2016, 44, 141-149.	3.1	20
61	T cell infiltration is associated with kidney injury in patients with anti-glomerular basement membrane disease. Science China Life Sciences, 2016, 59, 1282-1289.	4.9	22
62	Clinical Significance of IgM and C3 Glomerular Deposition in Primary Focal Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1582-1589.	4.5	44
63	Antibodies to Î±5 chain of collagen IV are pathogenic in Goodpasture's disease. Journal of Autoimmunity, 2016, 70, 1-11.	6.5	19
64	Autoantibodies against Linear Epitopes of Myeloperoxidase in Antiâ€“Glomerular Basement Membrane Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 568-575.	4.5	18
65	Coexistence of Anti-Glomerular Basement Membrane Antibodies and Anti-Neutrophil Cytoplasmic Antibodies in a Child With Human Leukocyte Antigen Susceptibility and Detailed Antibody Description. Medicine (United States), 2015, 94, e1179.	1.0	5
66	Clinical and Immunologic Characteristics of Patients With ANCA-Associated Glomerulonephritis Combined With Membranous Nephropathy. Medicine (United States), 2015, 94, e1472.	1.0	11
67	Clinical Features and Outcomes in Patients With Membranous Nephropathy and Crescent Formation. Medicine (United States), 2015, 94, e2294.	1.0	11
68	Identification of Critical Residues of Linear B Cell Epitope on Goodpasture Autoantigen. PLoS ONE, 2015, 10, e0123277.	2.5	6
69	The Alternative Pathway of Complement Activation May Be Involved in the Renal Damage of Human Anti-Glomerular Basement Membrane Disease. PLoS ONE, 2014, 9, e91250.	2.5	36
70	The Authors Reply:. Kidney International, 2014, 85, 1470-1471.	5.2	0
71	The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy. Kidney International, 2014, 85, 945-952.	5.2	46
72	Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Medicine, 2014, 12, 81.	5.5	49

#	Article	IF	Citations
73	The distribution of IgG subclass deposition on renal tissues from patients with anti-glomerular basement membrane disease. BMC Immunology, 2013, 14, 19.	2.2	37
74	Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease. BMC Immunology, 2013, 14, 42.	2.2	5
75	Complement Activation Contributes to the Injury and Outcome of Kidney in Human Anti-glomerular Basement Membrane Disease. Journal of Clinical Immunology, 2013, 33, 172-178.	3.8	40
76	Association of Epitope Spreading of Antiglomerular Basement Membrane Antibodies and Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 51-58.	4.5	21
77	Prediction of Outcomes in Crescentic IgA Nephropathy in a Multicenter Cohort Study. Journal of the American Society of Nephrology: JASN, 2013, 24, 2118-2125.	6.1	85
78	Serum <scp>BAFF</scp> and <scp>APRIL</scp> might be associated with disease activity and kidney damage in patients with antiâ€glomerular basement membrane disease. Nephrology, 2013, 18, 209-214.	1.6	14
79	Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney International, 2013, 84, 366-372.	5.2	83
80	Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study. Nephrology Dialysis Transplantation, 2012, 27, 243-252.	0.7	31
81	Antibodies against Linear Epitopes on the Goodpasture Autoantigen and Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 926-933.	4.5	27
82	Influence of myeloperoxidase-catalyzing reaction on the binding between myeloperoxidase and anti-myeloperoxidase antibodies. Human Immunology, 2012, 73, 364-369.	2.4	4
83	Circulating antiâ€glomerular basement membrane autoantibodies against Î±3(IV)NC1 undetectable by commercially available enzymeâ€linked immunosorbent assays. Nephrology, 2012, 17, 160-166.	1.6	22
84	Influence of variable domain glycosylation on anti-neutrophil cytoplasmic autoantibodies and anti-glomerular basement membrane autoantibodies. BMC Immunology, 2012, 13, 10.	2.2	20
85	Advances in human antiglomerular basement membrane disease. Nature Reviews Nephrology, 2011, 7, 697-705.	9.6	77
86	Clinical Features and Outcomes of Antiâ€“Glomerular Basement Membrane Disease in Older Patients. American Journal of Kidney Diseases, 2011, 57, 575-582.	1.9	51
87	In Reply to â€˜The Influence of Age on the Clinical Features and Outcomes of Antiâ€“Glomerular Basement Membrane Diseaseâ€™. American Journal of Kidney Diseases, 2011, 58, 678-679.	1.9	1
88	The association of HLA-DQB1, -DQA1 and -DPB1 alleles with anti- glomerular basement membrane (GBM) disease in Chinese patients. BMC Nephrology, 2011, 12, 21.	1.8	18
89	Anti-Glomerular Basement Membrane Disease. Medicine (United States), 2011, 90, 303-311.	1.0	113
90	Comparison of characteristics of natural autoantibodies against myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis. Rheumatology, 2011, 50, 1236-1243.	1.9	40

#	Article	IF	Citations
91	Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney International, 2010, 78, 590-597.	5.2	111
92	Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. International Immunology, 2010, 22, 45-51.	4.0	51
93	Influence of myeloperoxidase by anti-myeloperoxidase antibodies and its association with the disease activity in microscopic polyangiitis. Rheumatology, 2010, 49, 2068-2075.	1.9	9
94	The Immunopathological Spectrum of Crescentic Glomerulonephritis: A Survey of 106 Patients in a Single Chinese Center. Nephron Clinical Practice, 2010, 116, c65-c74.	2.3	24
95	ANCA-associated vasculitis and anti-GBM disease: the experience in China. Nephrology Dialysis Transplantation, 2010, 25, 2062-2065.	0.7	35
96	FCGR2B gene polymorphism rather than FCGR2A, FCGR3A and FCGR3B is associated with anti-GBM disease in Chinese. Nephrology Dialysis Transplantation, 2010, 25, 97-101.	0.7	27
97	Levels of epitope-specific autoantibodies correlate with renal damage in anti-GBM disease. Nephrology Dialysis Transplantation, 2009, 24, 1838-1844.	0.7	58
98	The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. Clinical Immunology, 2009, 133, 245-250.	3.2	47
99	Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. Kidney International, 2009, 76, 1108-1115.	5.2	51
100	The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHÎ±3(IV)NC1 is associated with disease severity. Human Immunology, 2009, 70, 425-429.	2.4	52
101	Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrology Dialysis Transplantation, 2008, 23, 2868-2872.	0.7	32
102	Antigen and Epitope Specificity of Antiâ€“Glomerular Basement Membrane Antibodies in Patients with Goodpasture Disease with or without Anti-Neutrophil Cytoplasmic Antibodies. Journal of the American Society of Nephrology: JASN, 2007, 18, 1338-1343.	6.1	70
103	Characteristics and Outcome of Chinese Patients with Both Antineutrophil Cytoplasmic Antibody and Antiglomerular Basement Membrane Antibodies. Nephron Clinical Practice, 2007, 107, c56-c62.	2.3	29
104	Natural anti-GBM antibodies from normal human sera recognize Î±3(IV)NC1 restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease. Clinical Immunology, 2007, 124, 207-212.	3.2	28
105	Concurrent Antiglomerular Basement Membrane Disease and Immune Complex Glomerulonephritis. Renal Failure, 2006, 28, 7-14.	2.1	30
106	Characteristics and Prognosis of Chinese Patients with Anti-Glomerular Basement Membrane Disease. Nephron Clinical Practice, 2005, 99, c49-c55.	2.3	63
107	Avidity of anti-glomerular basement membrane autoantibodies was associated with disease severity. Clinical Immunology, 2005, 116, 77-82.	3.2	37